{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020466","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.227232+00:00","generated_at":"2026-06-02T22:18:28.779326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell reports Q1 net loss $60.7M; cash $526.3M; LYL797 data due this quarter","bullets":["Net loss $60.7M vs $67.0M YoY; non-GAAP net loss $37.5M vs $44.8M.","Cash, equivalents and securities $526.3M; expected to fund operations into 2027.","Initial Phase 1 data for LYL797 (ROR1 CAR T) expected this quarter from ≥20 patients.","LYL845 (TIL) Phase 1 data expected H2 2024; LYL119 IND submission expected this quarter.","R&D expenses $43.2M vs $44.6M; G&A $13.5M vs $19.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020466","json":"https://secwatch.observer/filing/0001628280-24-020466.json","markdown":"https://secwatch.observer/filing/0001628280-24-020466.md","text":"https://secwatch.observer/filing/0001628280-24-020466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/lyel-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:18:28.779326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7850c648b07b13c44d118c0464c46bb43551c577","claim":"Lyell Immunopharma, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $60.7 million.","evidence_excerpt":"On May 6, 2024, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $60.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ac4b75a14164bc4af56b019ceab92c26c3a3a1df","claim":"Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $60.7 million.","evidence_excerpt":"Lyell reported a net loss of $60.7 million for the first quarter ended March 31, 2024, compared to a net loss of $67.0 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828024020466/0001628280-24-020466-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"net loss of $60.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}